ALVO logo

Alvotech (ALVO)

$4.37

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ALVO

Market cap

$1.71B

EPS

0.1

P/E ratio

--

Price to sales

3.83

Dividend yield

--

Beta

0.11349

Price on ALVO

Previous close

$4.41

Today's open

$4.40

Day's range

$4.20 - $4.49

52 week range

$2.94 - $6.53

Profile about ALVO

CEO

Lisa Graver

Employees

1460

Headquarters

Luxembourg,

Exchange

NASDAQ Global Market

Shares outstanding

390431480

Issue type

Common Stock

ALVO industries and sectors

Healthcare

Pharmaceuticals

News on ALVO

Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript

Alvotech ( ALVO ) UBS Global Biopharma Conference 2026 November 17, 2026 9:00 AM EST Company Participants Robert Wessman - Founder & Executive Chairman Balaji Prasad - Chief Strategy Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.

news source

Seeking Alpha • a day ago

news preview

What Alvotech (ALVO) Said on Its Q3 Earnings Call

Alvotech NASDAQ: ALVO expects its full-year revenue and adjusted earnings to land near the lower end of its guidance range, as the biosimilar maker works to increase deliveries following a manufacturing slowdown.

news source

MarketBeat • Nov 12, 2026

news preview

Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update

REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update.

news source

GlobeNewsWire • Nov 11, 2026

news preview

Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates

Alvotech (ALVO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.

news source

Zacks Investment Research • Nov 11, 2026

news preview

Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know

Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Alvotech: The Market Is Still Pricing The Broken Factory

Alvotech is transitioning from supply remediation to throughput, with FDA-cleared facilities and multiple key biosimilar filings advancing toward decisions this quarter. ALVO's guidance implies a significant second-half revenue and EBITDA ramp, hinging on restored manufacturing capacity and upcoming product launches. Recent manufacturing upgrades and expanded partnerships position ALVO to compete on supply reliability and cost, crucial in crowded biosimilar markets.

news source

Seeking Alpha • Nov 3, 2026

news preview

Alvotech to Present at Upcoming Investor Conferences in November

REYKJAVIK,  ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that members of the management team will participate in upcoming investor conferences in November as follows:

news source

GlobeNewsWire • Nov 2, 2026

news preview

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

REYKJAVIK,  ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the nine months and third quarter ended September 30, 2026 on Wednesday, November 11, 2026, after the U.S. market close.

news source

GlobeNewsWire • Oct 28, 2026

news preview

New Strong Sell Stocks for October 21st

ALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.

news source

Zacks Investment Research • Oct 21, 2026

news preview

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio

news source

GlobeNewsWire • Oct 20, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Alvotech

Open an M1 investment account to buy and sell Alvotech commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ALVO on M1